KOMODO DRUG PROJECTIONS
 
 

Komodo Drug Projections

A New Standard for Superior Projections

  • Bullet wrapper 1

    Real-world, real-time, real-simpleAccess weekly, high-quality national projections for market baskets encompassing 10,000+ Rx and Mx benefit drugs and 3,000+ molecules via MapView™’s no-code workflow.

  • Bullet wrapper 1

    Trusted and transparent: We bring together projected and observed data, confidence intervals, and time travel functionalities to provide deeper context and greater transparency.

  • Bullet wrapper 1

    Data advantage: Leverage the power of Komodo's Healthcare Map™ data foundation. Unlike traditional RX-only insights, our source selection, integration, characterization, and statistical modeling support a robust Projections model. 

  • Bullet wrapper 1

    Forthcoming releasesStay ahead with our innovation roadmap featuring upcoming sub-national and compound Rx modeling capabilities to enhance your analytics.

122-Webinar-Banner-2b

Talk to an Expert

122-Webinar-Banner-2b

A MARKET ACCESS WEBINAR

No Code Required: Define, Build, and Generate Payer Insights

Listen in as we introduce MapView™ for Market Access teams. Our new solution delivers a no-code option directly into the hands of Market Access professionals.

Learn How:

bulb-solid-black 1
Discover the payers that matter to your therapeutic area
magnifying glass-solid-black-1-1
Identify top potential HCPs and HCOs based on payer population

 

 

analytics-solid-black-1
Assess competitive trends across your market basket by payer channel, payer, and HCP/HCO

Request Your Demo

Transform Decision-Making With Solutions For Every Team

Investor Reporting
Investor Reporting

Leverage accurate forecasting in specialty and medical benefit drugs to provide leadership and investors with precise insights in a challenging market landscape.

Market Share Monitoring
Market Share Monitoring

Track market share and expected/projected market share at the brand and molecule level and identify gaps and areas of opportunity in complex markets.

Competitive Intelligence
Competitive Intelligence

Gain insights into competitive market share at the brand and molecule level to prioritize areas of focus, particularly in complex classes where therapies may be classified as Rx or Mx.

Market Sizing
Market Sizing

Identify the most viable market opportunities to deploy resources and focus for maximum impact.

Launch Modeling
Launch Modeling

Construct launch curves to assess launch uptake for a new drug or indication based on relevant analogs.

Validation of Other Analyses
Validation of Other Analyses

Use observed vs. projected data to confirm analysis in other MapView dashboard templates and other modeling tools.

  • Investor Reporting
    Investor Reporting

    Leverage accurate forecasting in specialty and medical benefit drugs to provide leadership and investors with precise insights in a challenging market landscape.

  • Market Share Monitoring
    Market Share Monitoring

    Track market share and expected/projected market share at the brand and molecule level and identify gaps and areas of opportunity in complex markets.

  • Competitive Intelligence
    Competitive Intelligence

    Gain insights into competitive market share at the brand and molecule level to prioritize areas of focus, particularly in complex classes where therapies may be classified as Rx or Mx.

  • Market Sizing
    Market Sizing

    Identify the most viable market opportunities to deploy resources and focus for maximum impact.

  • Launch Modeling
    Launch Modeling

    Construct launch curves to assess launch uptake for a new drug or indication based on relevant analogs.

  • Validation of Other Analyses
    Validation of Other Analyses

    Use observed vs. projected data to confirm analysis in other MapView dashboard templates and other modeling tools.

Success Stories
Michael Townsend
Michael Townsend
Research Director
Life Sciences Commercial Strategies
idc
“Komodo’s full-stack platform approach enables a comprehensive foundation for healthcare analytics, allowing Life Sciences and healthcare companies to generate critical insights across the industry.”
Joey Mattingly Hex
Joey Mattingly, PharmD, MBA, PhD
Associate Professor Research Director
University of Maryland
“With Komodo’s research-grade insights and technology, we will now have unprecedented visibility into the full range of factors that contribute to healthcare outcomes, including the historically overlooked role of social determinants.”
Tom Haskell
Tom Haskell
Global Head of Innovation, Data, and Analytics
kantar
“Komodo allows us to unlock richer insights by integrating our own data with the Healthcare Map, all on the Sentinel platform. In our experience with real-world-evidence research, this technology has played a pivotal role in offering a timely, comprehensive, and accurate view of patient journeys to drive evidence around disease burden and health outcomes.”